¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"single dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • air dose
    °ø±â¼±·®
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®·ü
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • booster dose
    1. Ãß°¡¿ë·® 2. Ãß°¡Á¢Á¾·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed dose equivalent
    ¿¹Å¹¼±·®ÇØ´ç·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • cumulative dose
    1. ´©Àû¿ë·® 2. ´©Àû¼±·®
  • curative dose
    1. Ä¡À¯¿ë·® 2. Ä¡À¯¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • depth dose curve
    ½ÉºÎ¼±·®°î¼±
  • dose
    1. ¿ë·®, Åõ¿©·® 2. ¼±·®, Á¶»ç·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • absorbed dose rate
    Èí¼ö¼±·®·ü
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • acceptable daily dose
    ÀÏÀÏÇã¿ë·®
  • air dose
    °ø±â¼±·®
  • average dose
    Æò±Õ¿ë·®, Æò±Õ¼±·®
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • booster dose
    Ãß°¡Á¢Á¾·®, Ãß°¡¿ë·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • collective equivalent dose
    Áý´Ü´ç·®¼±·®
  • committed dose equivalent
    ¿¹Å¹¼±·®ÇØ´ç·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • committed equivalent dose
    ¿¹Å¹´ç·®¼±·®
  • cumulative dose
    ´©Àû·®, ´©Àû¼±·®
  • curative dose
    Ä¡À¯¿ë·®, Ä¡À¯¹æ»ç¼±·®
  • depth dose curve
    ½ÉºÎ¼±·®°î¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • head drop dose =HD
    µÎºÎ Ãß¶ô·®(¡­õÍÕªåÖ).
  • heat dose equivalent
    ¿­¼±·®´ç·®
  • high dose rate
    °í¼±·®À²
  • high dose rate intraluminal radiotherapy
    °í¼±·®À² °ü³»¹æ»ç¼±Ä¡·á
  • high dose tolerance
    °ú·®°ü¿ë
  • immunizing dose
    ¸é¿ª·®(Øóæ¹åÖ).
  • incident dose
    ÀԻ缱·®
  • ineffective dose
    ¹«È¿·®(ÙíüùåÖ).
  • infectious(-tive) dose
    °¨¿°À¯¹ß·®
  • infective dose
    °¨¿° À¯¹ß·®
  • priming dose
    ÃÊȸ·®, ÃæÁø·®
  • priming dose
    ÃÊȸ°¨ÀÛ ¿ë·®
  • priming dose
    ÃÊȸÇ׿øÀڱط®.(¾à¸®)ÃÊȸ(¿ë)·®.
  • priming dose
    ÃÊȸÇ׿øÀڱط®.[¾à¸®]ÃÊȸ(¿ë)·®, ºÎÇÏ(¿ë)·®.
  • quasithreshold dose, Dq
    ÁØÇѰ輱·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • single injection technic s. shot technic
    ÀÏȸÁÖÀϹý, ´ÜÀÏÁÖ»ç¹ý( Ó¤ìéñ¼ÞÒÛö).
  • single investing method
    1ȸ¸Å¸ô¹ý(ìéüÞØØÙÒÛö).
  • single linkage
    ´ÜÀÏ¿¬¼â(¡­ææáð)
  • single loop wiring
    ´Ü¼ø°í¸®»ó°áÂû (¡­»ó°áÂû).
  • single major gene(locus) model
    ´ÜÀÏ ÁÖ¿äÀ¯ÀüÀÚ(À¯ÀüÁÂÀ§) ¸ðµ¨
  • single metastasis
    ´ÜÀÏÀüÀÌ
  • single outlet heart
    ´ÜÀÏÀ¯Ãâ·Î½ÉÀå.
  • single outlet heart
    ´ÜÀÏÀ¯Ãâ·Î½ÉÀå(Ó¤ìé×µõóÖØ ãýíô)
  • single ovum twin
    À϶õ¼º ½Ö»ý¾Æ(ìéÕ°àõ äªßæä®).
  • single pass technique
    1ȸ Åë°ú ±â¹ý (ìéüÞ ÷×Φ ÐüÛö)
  • single pass technique
    ´ÜÀÏ Åë°ú ±â¹ý
  • single photon emission computed tomography (SPECT)
    ´ÜÀϱ¤ÀÚ¹æÃâÀü»êÈ­´ÜÃþÃÔ¿µ
  • single photon emission computed tomography(SPECT)
    ´ÜÀϾçÀÚ¹æÃâÀü»êÈ­ ´ÜÃþÃÔ¿µ¼ú
  • single photon emission tomography(SPECT)
  • single pregnancy
    ´ÜÅÂÀÓ½Å(Ó¤÷Ãìôãã).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • median toxic dose
    Á¤Áß µ¶¼º·®(ïáñéÔ¸àõÕá)
  • minimum hemagglutinating dose
    ÃÖ¼ÒÇ÷±¸ÀÀÁý·®(õÌá³úìϹëêó¢Õá)
  • minimum hemolytic dose
    ÃÖ¼Ò¿ëÇ÷·®(õÌá³éÁúìÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • permissible dose
    Çã¿ë·®(úÉé»Õá)
  • priming dose
    ÀÏÂ÷󸮿뷮(ìéó­ô¥×âéÄÕá)
  • radiation absorbed dose
    ¹æ»ç¼± Èí¼ö·®(Û¯ÞÒàÊýåâ¥Õá)
  • radiation dose
    ¹æ»ç¼±·®(Û¯ÞÒàÊÕá)
  • threshold dose
    ¹®ÅÎ ¼±·®(àÊÕá)
  • tissue culture infectious dose
    Á¶Á÷¹è¾ç °¨¿°·® (ðÚòÄÛÆå×ÊïæøÕá)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SPC salicylamide, phenacetin, and caffeine; seropositive carrier; single palmar crease; single photoelec...
SSB short spike burst; sicca syndrome B; single-strand break; single-stranded binding [protein]; stereos...
SUA serum uric acid; single umbilical artery; single unit activity
SDS same day surgery; school dental services; self-rating depression scale; sensory deprivation syndrome...
SSD shaded surface display; single saturating dose; Social Security disability; source-skin distance; so...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DAP Dose area product
DLT Dose limiting toxicities
DLT Dose limiting toxicity
DMF Dose modification factors
DRC Dose response curves
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • curative dose
    ġȿ·®
  • daily dose
    ÀÏÀÏ·®, ÀϿ뷮
  • dose calculation
    ¼±·® °è»ê
  • dose commitment
    ¼±·® ¿¹Å¹
  • dose costraint
    ¼±·® ±¸¼ÓÄ¡
  • dose equivalent
    ¼±·® ´ç·®
    ¹æ»ç¼±ÀÇ ½ÇÈ¿Àû ¼±·®. ¹æ»ç¼± ¹æÈ£ ÀÔÀå¿¡¼­ Á¾·ù³ª ¿¡³ÊÁö°¡ ´Ù¸¥ ¹æ»ç¼±ÀÌ »ýü¿¡ ¹ÌÄ¡´Â È¿°ú¿¡ ÁÖ¸ñÇÏ¿© ±Ù³â¿¡ ¿Í¼­ Á¤ÀǵǾú´Ù. ´ÜÀ§´Â remÀÌ´Ù.
  • dose limit
    ¼±·® Çѵµ, ¼±·® Á¦ÇÑ
  • dose modifying factor
    ¼±·® ¼ö½Ä °è¼ö
  • dose profile
    ¼±·® Ãø¸éµµ
  • dose rate effect
    ¼±·®À² È¿°ú
  • dose rate variation
    ¼±·®·ü º¯È­
  • dose response relationship
    ¹æ»ç¿ë·® ¹ÝÀÀ °ü°è, ¿ë·® ¹ÝÀÀ °ü°è
  • dose-effect relationship
    ¼±·® ¿µÇâ °ü°è
  • dose-equivalent limit
    ¼±·® ´ç·® Çѵµ
  • dose-response curve
    ¿ë·® ¹ÝÀÀ °î¼±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
booster dose A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies.
(05 Mar 2000)
breast dose in mammography <radiology> 180 mrad / view -- mid-breast dose, guideline: less than 1 rad for 2-view exam
(12 Dec 1998)
maintenance dose In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
genetically significant dose <physics, radiobiology> The genetically significant dose is that which, if received by every member of the population, would be expected to produce the same genetic injury to the population as do the actual doses received by the individuals irradiated.
Thus, the genetically significant dose is the dose equivalent to the gonads weighted for the age and sex distribution in those members of the irradiated population expected to have offspring. The genetically significant dose is expressed in sieverts (or rem).
Acronym: GSD
(06 Aug 1998)
maximal dose <pharmacology> The largest amount of a drug or physical procedure that an adult can take with safety.
(05 Mar 2000)
maximum permissible dose <radiobiology> Defined by the International Commission on Radiological Protection as the greatest dose of radiation which, in the light of present knowledge, is not expected to cause detectable bodily injury to a person at any time during his lifetime.
This dose has been reduced with each Commission report. The MPD is given in terms of acute or chronic exposure of the whole body or of organs, systems, or regions of the body, and differs for persons who are occupationally exposed versus the public at large.
(05 Mar 2000)
median effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
gonadal dose The exposure dose to the male or female gonad, usually from incidental secondary radiation in diagnostic or therapeutic irradiation, or from whole-body irradiation.
Synonym: gonadal dose.
(05 Mar 2000)
gonad dose The exposure dose to the male or female gonad, usually from incidental secondary radiation in diagnostic or therapeutic irradiation, or from whole-body irradiation.
Synonym: gonadal dose.
(05 Mar 2000)
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
cumulative dose The total dose resulting from repeated exposures to radiation of the same part of the body or of the whole body.
(05 Mar 2000)
curative dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á